Möhring, C., Berger, M., Sadeghlar, F., Zhou, X., Zhou, T., Monin, M. B., . . . González-Carmona, M. A. (2025). Evaluating sorafenib (SORA-2) as second-line treatment for unresectable hepatocellular carcinoma: A European retrospective multicenter study. Cancers, 17(6), . https://doi.org/10.3390/cancers17060972
Chicago-Zitierstil (17. Ausg.)Möhring, Christian, et al. "Evaluating Sorafenib (SORA-2) as Second-line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study." Cancers 17, no. 6 (2025). https://doi.org/10.3390/cancers17060972.
MLA-Zitierstil (9. Ausg.)Möhring, Christian, et al. "Evaluating Sorafenib (SORA-2) as Second-line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study." Cancers, vol. 17, no. 6, 2025, https://doi.org/10.3390/cancers17060972.